Ebanga (Ansuvimab-Zykl) 400Mg/Vial Lyophilized Powder for Injection

BLA 761172 BLA APPROVAL Ridgeback Biotherapeutics, LP Attention: Stacy McIntosh SVP, Regulatory Affairs 3162 Commodore Plaza, Suite 3E Coconut Grove, FL 33133-5815 Dear Ms. Mcintosh: Please refer to your biologics license application (BLA) dated May 29, 2020, received May 29, 2020, and your amendments, submitted under section 351(a) of the Public Health Service Act for Ebanga (ansuvimab-zykl) 400mg/vial lyophilized powder for injection. LICENSING We have approved your BLA for Ebanga (ansuvimab-zykl) effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Ebanga under your existing Department of Health and Human Services U.S. License No. 2162. Ebanga is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection. MANUFACTURING LOCATIONS Under this license, you are approved to manufacture Ebanga drug substance and drug (b) (4) product at . The final drug product will be (b) (4) labeled and packaged at . You may label your product with the proprietary name, Ebanga, and market it as 400 mg lyophilized powder for injection in a single-dose vial. DATING PERIOD The dating period for Ebanga shall be 12 months from the date of manufacture when stored at 2 – 8°C. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall (b) (4) be (b) (4)months from the date of manufacture when stored at °C. Results of ongoing stability studies should be submitted throughout the dating period, as they become available, including the results of stability studies from the first three production lots. Reference ID: 4720395 BLA 761172 Page 2 We have approved the stability protocol(s) in your license application for the purpose of extending the expiration dating period of your drug substance and drug product under 21 CFR 601.12. FDA LOT RELEASE You are not currently required to submit samples of future lots of Ebanga to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot. Any changes in the manufacturing, testing, packaging, or labeling of Ebanga, or in the manufacturing facilities, will require the submission of information to your biologics license application for our review and written approval, consistent with 21 CFR 601.12. APPROVAL & LABELING We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling. CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov.1 Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information). Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As. 2 The SPL will be accessible via publicly available labeling repositories. CARTON AND CONTAINER LABELING Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain 1 http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm 2 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at https://www.fda.gov/RegulatoryInformation/Guidances/default.htm. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 4720395 BLA 761172 Page 3 Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved BLA 761172.” Approval of this submission by FDA is not required before the labeling is used. MATERIAL THREAT MEDICAL COUNTEMEASURE PRIORITY REVIEW VOUCHER We also inform you that you have been granted a material threat medical countermeasure priority review voucher (PRV), as provided under section 565A of the Federal Food, Drug and Cosmetic Act (FDCA). This PRV has been assigned a tracking number, PRV BLA 761172. All correspondences related to this PRV should refer to this tracking number. This PRV entitles you to designate a single human drug application submitted under section 505(b)(1) of the FDCA or a single biologics license application submitted under section 351 of the Public Health Service Act as qualifying for a priority review. Such an application would not have to meet any other requirements for a priority review. This PRV may be transferred by you to another sponsor of a human drug or biologic application. If the PRV is transferred, the sponsor to whom the PRV has been transferred should include a copy of this letter (which will be posted on our Web site as are all approval letters) and proof that the PRV was transferred. When redeeming this PRV, you should refer to this letter as an official record of the voucher. The sponsor who redeems the PRV must notify FDA of its intent to submit an application with a PRV at least 90 days before submission of the application and must include the date the sponsor intends to submit the application. FDA has published a draft guidance, Material Threat Medical Countermeasure Priority Review Vouchers, at https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm592548.pdf. This guidance, when finalized, will represent the current thinking of the FDA on this topic. ADVISORY COMMITTEE Your application for Ebanga was not referred to an FDA advisory committee because: (1) the clinical trial design is acceptable (2) the application did not raise significant safety or efficacy issues that were unexpected for a drug/biologic of this class in the intended population (3) the application did not raise significant public health questions on the role of the biologic in the diagnosis, cure, mitigation, treatment, or prevention of a disease U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 4720395 BLA 761172 Page 4 REQUIRED PEDIATRIC ASSESSMENTS Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement. POSTMARKETING REQUIREMENTS UNDER 505(o) Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute. We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess a signal of serious risk of emergence of Ebola virus resistance to Ebanga. Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk. Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following studies: 3965-1 Conduct a study to identify all amino acid polymorphisms in the ansuvimab-zykl epitope (GP positions 111-119) and amino acids within 5 Angstroms from currently available Zaire ebolavirus (EBOV) GP sequences in public databases and perform phenotypic assessments to determine the impact that each of the substitutions have on ansuvimab zykl neutralization using lentivirus-based particles pseudotyped with EBOV GP containing each of the substitutions. Also include EBOV GP substitutions L111I and L111F in your phenotypic analyses. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 4720395 BLA 761172 Page 5 The timetable you submitted on November 2, 2020, states that you will conduct this study according to the following schedule: Study Completion: 09/2022 Final Report Submission: 03/2023 3965-2 Conduct a study to identify ansuvimab-zykl resistance pathways using a recombinant virus expressing Zaire ebolavirus (EBOV) glycoprotein (GP) to select and characterize several independent resistant isolates phenotypically and genotypically. The timetable you submitted on November 2, 2020, states that you will conduct this study according to the following schedule: Study Completion: 09/2022 Final Report Submission: 03/2023 FDA considers the term final to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.3 Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your BLA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate: Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).

Load more